



NEWS RELEASE  
FOR IMMEDIATE RELEASE

TSX: AMF

### **AMORFIX SHEEP SCRAPIE RESULTS FROM BLINDED PANELS PRESENTED AT INTERNATIONAL PRION CONFERENCE**

**TORONTO, ON, October 8, 2008** – Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced that Dr. Neil Cashman, Chief Scientific Officer of Amorfix, will present a poster describing the sheep scrapie results from two blinded sheep scrapie panels using Amorfix's prototype EP-TSE™ Blood Screening Assay at the Prion 2008 Conference today in Madrid, Spain. The presentation entitled, "Detection of prions in blood from asymptomatic scrapie sheep using Epitope Protection technology" highlights the sensitivity and specificity of the EP-TSE™ sheep scrapie assay.

Dr. Philip Minor, Head of Virology Division of the National Institute for Biological Standards and Control (NIBSC), the UK agency that prepared the blinded panels, will also present blinded panel results for Amorfix's EP-vCJD™ Blood Screening Assay and the more recent sheep scrapie results in his presentation entitled "Blood based assays for infection with the agent of vCJD".

"There are approximately 100 million blood donations collected every year and blood transfusion services outside of Europe must reject donors who have traveled in Europe during the BSE outbreak. All countries struggle to collect enough blood and our test for vCJD would allow more people to be blood donors and stabilize the blood system worldwide," said Dr. George Adams, Chief Executive Officer of Amorfix. "We continue to work closely with NIBSC and the UK National Blood Service with the goal of testing human vCJD patient blood samples for final assay validation."

Scrapie is an infectious prion disease in sheep similar to Mad Cow disease (BSE) in cattle but without the known transmission risk to humans of BSE. Amorfix developed its sheep scrapie prion-detection assay to support the commercialization of its leading EP-vCJD™ Blood Screening Assay currently in late stage product validation. Due to the low number of blood samples from people who have suffered from vCJD being available for large scale assay validation, the UK government requires manufacturers to demonstrate that their blood screening technology can detect prions in an animal model of the disease. Amorfix tested samples from two NIBSC blinded panels of normal and scrapie sheep that were symptomatic for the disease to show that the test can differentiate between normal sheep and sheep with prion disease.

#### **About Amorfix**

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's

Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

*This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

- 30 -

**For more information, please contact:**

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---